Inhatarget Therapeutics
1 clinical trials · Sponsor
◉ Watch Inhatarget Therapeutics
| Record | Firm | Date |
|---|---|---|
| Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer (NCT06896890) | Inhatarget Therapeutics | 2023-06-23 |
Track Inhatarget Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.